
|Articles|April 19, 2004
New antidepressant offers substantial savings
Patients in need of, or currently receiving, selective serotonin reuptake inhibitor (SSRI) therapy now have a branded formulation of paroxetine that is bioequivalent to paroxetine hydrochloride (Paxil, GlaxoSmithKline), yet available at a significant discount. The FDA recently approved paroxetine (Pexeva, Synthon Pharmaceuticals) mesylate for the treatment of major depressive disorder, obsessive/compulsive disorder (OCD), and panic disorder. The product is currently available in pharmacies.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
GoodRx Offers Wegovy Weight-Loss Pill at Under $150 a Month
2
Bepirovirsen Meets Primary End Point for Functional Cure Rate of Hepatitis B
3
The PBM Putting Pharmacists at the Center of Formulary Design
4
HHS Limits Vaccine Recommendations for Childhood Schedules
5










































































































































































































